Company’s focus is on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies New corporate tagline and website introduced New ticker symbol to be NYSE American: CATX RICHLAND, WASHINGTON & CORALVILLE, IOWA – February...
Newsroom
Isoray To Announce Fourth Quarter and Fiscal Year End 2021 Financial Results on September 21, 2021
Conference Call is Tuesday, September 21 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – September 9, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body,...
Isoray Announces Third Quarter Fiscal 2021 Financial Results
Revenue Increased 10% Sequentially Record Non-Prostate Brachytherapy Revenue Increased 20% Year-Over-Year RICHLAND, WASHINGTON – May 13, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering...
Isoray To Announce Third Quarter Fiscal 2021 Financial Results on May 13, 2021
Conference Call is Thursday, May 13 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – April 29, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body, today...
University Hospitals Cleveland Medical Center Pilot Study Shows Promise for High-Risk Recurrent Head and Neck Cancer Treatment with Cesium-131 and Surgical Resection
RICHLAND, WASHINGTON – March 31, 2021 – A recently published small prospective series of patients with recurrent head and neck (H&N) cancers treated with surgical resection and Isoray’s Cesium-131 brachytherapy found potential benefits that support further...
Isoray to Present at the Oppenheimer 31st Annual Healthcare Conference
RICHLAND, WASHINGTON – March 3, 2021 – Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator, today announced that Chief Executive Officer Lori Woods will present at the Oppenheimer 31st Annual Healthcare Conference on...
Isoray Announces the Appointment of Lisa Lauer As Vice President Business Development
RICHLAND, WASHINGTON – February 16, 2021 – Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator, today announced that Lisa Lauer has been appointed Vice President, Business Development. CEO Lori Woods says Lauer’s...
Isoray Announces Second Quarter Fiscal 2021 Financial Results
Revenue Increased 7% Year-Over-Year Non-Prostate Brachytherapy Revenue Increased 92% Year-Over-Year RICHLAND, WASHINGTON – February 9, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding...
Isoray To Announce Second Quarter Fiscal 2021 Financial Results on February 9, 2021
Conference Call is Tuesday, February 9, 2021 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – February 5, 2021– Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the...
Isoray Announces Pricing of $45 Million Public Offering
RICHLAND, Wash., February 4, 2021 - Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced the pricing of its public offering of 36,000,000 shares of its...
Isoray Announces Proposed Underwritten Public Offering
RICHLAND, Wash., February 3, 2021 - Isoray, Inc. (NYSE AMERICAN: ISR) (“Isoray” or the “Company”), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it intends to offer and...
Isoray to Present at the H.C. Wainwright BioConnect 2021 Conference
RICHLAND, WASHINGTON – January 7, 2021 – Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator powering expanding treatment options throughout the body, today announced that Chief Executive Officer Lori Woods will present at...
C4 Imaging Announces Sirius Positive Signal MRI Marker Given FDA 510(k) Clearance for Use with Isoray’s Cesium-131 Brachytherapy Seeds to Treat Prostate Cancer
HOUSTON, TEXAS - January 05, 2021 – C4 Imaging LLC is pleased to announce that Isoray Medical, Inc. (NYSE American: ISR) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the use of C4 Imaging’s Sirius® positive-signal MRI (Magnetic Resonance...